Cannim and Medisun are merging, thus expanding Cannim's reach to include four continents. Based in southwestern Ontario, Medisun clones 1 million cannabis plants per year and produces up to 1000 kg of medicinal-quality cannabis each week from a five-hectare climate-controlled facility. The merged company will continue under the Cannim name and remain headquartered in Sydney.
Cannim Chair John Worton described the merger as a momentous step for the companies: “Medisun’s quality, large scale cultivation expertise complements Cannim’s strengths in regulatory compliance, operations, and the establishment of channels to market. Uniting the two companies greatly increases our ability to source and supply quality product to key international markets. Crucially, the merger will introduce Cannim to the burgeoning legal adult-use segment, making it the leading Australian company in this space.”
Medisun Chair Friedwart Barfod, based in the Netherlands, will join Cannim’s board alongside another recent appointee, Dr. Costa Boyages, who is on the board of the Australian Medical Association (NSW) and the NSW Rural Doctors Network. Completing the board of the merged entity is New York-based Steve Ezzes, who served as a Director of OzEmail, and Nick Selvaratnam, formerly the head of Credit Suisse equity capital markets in Australia. Medisun’s Chief Operations Officer, Laust Dam, who has over 30 years of experience in intensive agriculture, will join Cannim’s C-suite as Chief Cultivation Officer and oversee the continued development of Cannim’s two 500-acre farms in Australia and Jamaica.
For more information: